Find a clinical trial
Affidea brustCare is a leading centre of excellence that treats patients according to the highest scientific standards and actively participates in national and international breast cancer research.
Clinical trials at Affidea brustCare
At Affidea brustCare, patients can gain access to the latest breast cancer therapies and treatment methods as part of clinical trials. These therapies and methods are otherwise unavailable outside of trials but have already shown promising initial results.
Our doctors are closely networked with national and international research groups and are in regular dialogue with advisors from pharmaceutical companies regarding new oncological drugs.
Over the past few decades, clinical trials have yielded many new findings in the early detection, diagnosis and treatment of breast cancer, leading to the establishment of new diagnostic and therapeutic methods.
Ongoing participation in clinical trials is therefore a key means of ensuring that our patients continue to have access to innovative therapies in the future – always with the aim of offering state-of-the-art medical care.
Why take part in a clinical trial?
Patients may decide to take part in clinical trials for a variety of reasons:
- To access new, promising therapies that may be more effective or better tolerated
- To benefit from close monitoring and care by a dedicated medical team
- To contribute to improving the treatment of breast cancer through their participation
These trials help to:
- Avoid unnecessary treatments
- Obtain more detailed information about dosage and effects
- Measure quality of life and side effects of treatment
- Assess the value of additional tests
- Disseminate new findings via a global network of collaborating study groups
- Prolong life while maintaining quality of life
What you should know before taking part in a trial
Affidea brustCare provides access to selected national and international clinical trials that must meet strict ethical and scientific standards.
Our team will explain your options and support you every step of the way.
Before joining a trial, you will receive detailed information about the treatment being trialled, its potential benefits and any possible risks.
You will also be given detailed information about how the trial will run, i.e. about the tests and appointments specified in the trial protocol.
You will then have adequate time to consider your participation in the study, discuss it with your relatives or other people, and clarify any questions you may have with your doctor and the trial team.
Quality standards in clinical research
- All trials available at our centres are reviewed and approved by the Ethics Committee of the Canton of Zurich and, where necessary, by Swissmedic.
- The trials are conducted in accordance with internationally recognised guidelines, known as Good Clinical Practice (GCP), which include ethical and scientific quality standards to protect the rights, safety and dignity of participants and to ensure reliable data from the trial.
- Our medical staff are trained to accompany our patients throughout the process and ensure that every step complies with these ethical and clinical standards.
- Before taking part in any trial, patients receive detailed information about the treatment and are given sufficient time to consider their decision.
- Participation in a trial is always voluntary. Patients may withdraw from the trial at any time without this having any negative impact on their ongoing treatment.
- Your safety and well-being are our top priority.
Who can take part in a clinical trial?
Every clinical trial follows precisely defined criteria that determine which patients can be included in the trial in question.
This ensures that the trial is safe for participants and that the results are reliable.
These criteria may include, for example:
- The type and stage of your breast cancer
- Your previous treatments
- Your medical history
- Your age and general state of health
If you are interested in taking part in a trial, the first step is to talk to your doctor or an investigating clinician from the trial team. They can help you find a suitable trial and explain what participation entails.
If no trial is suitable, you will still receive the best possible medical care.
Our team will be happy to assist you and help you understand all your options.
Find a breast cancer clinical trial
CAMBRIA-2
Trial ID: NCT05952557
- Phase III clinical trial
- For patients with hormone receptor-positive, Her2-negative early-stage breast cancer with intermediate or high risk
- Patients are randomly assigned to one of two treatments (randomisation):
- Arm A: Standard adjuvant endocrine therapy (at the doctor’s discretion)
- with or without CDK4/6 inhibitor (Abemaciclib) for seven years.
- Arm B: Adjuvant endocrine therapy with Camizestrant (SERD) with or without CDK4/6 inhibitor (Abemaciclib) for seven years
- As of August 2025: No longer possible to include patients with indications for CDK4/6 inhibitors or patients without lymph node metastases (pN0).
ELEGANT
- Phase III clinical trial
- For hormone receptor-positive, Her2-negative early-stage breast carcinoma with a high risk of recurrence (with lymph node metastases).
- Participants who have received endocrine therapy (AIs or tamoxifen, +/- LHRH agonists) with or without CDK4/6 inhibitors for at least 24 months but no longer than 60 months. The patients are randomly assigned to one of two treatments:
- Arm 1: Elacestrant (endocrine therapy, known as SERD) for 5 years +/- LHRH agonist
- Arm 2: Standard adjuvant endocrine therapy (at the doctor’s discretion) over the course of 5 years
IZABRIGHT
- Phase II/III clinical trial
- For patients with previously untreated, locally advanced, recurrent inoperable or metastatic triple-negative breast cancer or oestrogen receptor-low (ER <10%), Her2-negative breast cancer, who are not eligible for anti-PD1/PD-L1 treatment
- 1. Phase II: The patients are randomly assigned to one of three treatments:
- Arm A1: Izalontamab Brengitecan 2.0 mg/kg (antibody-drug conjugate, BMS-986507)
- Arm A2: Izalontamab Brengitecan 2.5 mg/kg (antibody-drug conjugate, BMS-986507)
- Arm B: Doctor's choice of treatment (Paclitaxel, Capecitabine, Carboplatin plus Gemcitabine)
- 2. Phase III: The patients are randomly assigned to one of two treatments:
- Arm A: Izalontamab Brengitecan at RP3D (antibody-drug conjugate, BMS-986507)
- Arm B: Doctor's choice of treatment
MELODY
Trial ID: NCT05559411 (EUBREAST 4)
- Non-interventional observational study
- For patients with invasive breast carcinoma or DCIS prior to planned breast-conserving surgery with image-guided localisation of the primary tumour
- The trial collects data on treatment outcomes and the satisfaction of practitioners and patients.
MK2870-010 / TroFuse 010
Trial ID: NCT06312176
- Phase III clinical trial
- For patients with hormone receptor-positive, Her2-negative breast cancer that is locally advanced and inoperable or metastatic.
- The patients have already undergone endocrine therapy (anti-hormone therapy) and taken a CDK4/6 inhibitor, but the tumour has continued to spread.
- The patients must not yet have received chemotherapy.
- The patients are randomly assigned to one of three treatments:
- Sacituzumab Tirumotecan (antibody-drug conjugate, MK-2870)
- Sacituzumab Tirumotecan (antibody-drug conjugate, MK-2870) plus Pembrolizumab (immunotherapy)
- Chemotherapy (treatment chosen by the doctor)
MK2870-012 / TroFuse 012
- Phase III clinical trial
- For patients with early-stage triple-negative breast cancer and incomplete pathological response after neoadjuvant treatment based on the KEYNOTE-522 treatment plan (Pembrolizumab with Carboplatin/Taxanes and Pembrolizumab with anthracycline-based chemotherapy).
- Patients are randomly assigned to one of two treatments (randomisation):
- Arm 1: Sacituzumab Tirumotecan (antibody-drug conjugate, MK-2870) plus Pembrolizumab (immunotherapy)
- Arm 2: Doctor’s choice of treatment: Pembrolizumab or Pembrolizumab plus Capecitabine (chemotherapy)
VISION-1
Trial ID: NCT04289935 (OPBC-06)
- Prospective feasibility study
- For patients with:
- Unifocal, histologically confirmed invasive breast carcinoma and previous neoadjuvant chemotherapy with radiologically complete response or near complete response in MRI imaging or ultrasound
- Initial tumour size between 1–5 cm(cT1c to cT2), any N status, M0
- Procedure: Patients undergo an intelligent vacuum-assisted biopsy before surgery, followed by the standard planned operation.
- Aim: To investigate whether imaging techniques and intelligent vacuum-assisted tissue biopsy are sufficient in certain breast cancer patients to determine the effectiveness of chemotherapy administered prior to tumour surgery.
Completed trials
Completed trials (in follow-up)
POSITIVE trial (IBCSG 48/14): Trial among female patients of childbearing potential after 1.5–2.5 years of endocrine therapy.
PALLAS trial (ABCSG 42): Endocrine therapy +/- palbociclib (CDK4/6 inhibitor) in patients with hormone-sensitive breast carcinoma.
ABCSG33R trial: Axillary registry for sentinel lymph node metastases without axillary dissection.
TARGIT-B trial (UCL London): Intraoperative boost (IORT) vs. conventional.
PREPEC trial (OPBC-02/PREPEC): Prepectoral vs. subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy.
LidERA trial (Roche GO42784, CRO: PEP): Adjuvant endocrine therapy with giredestrant (oral SERD) vs. endocrine therapy of choice for 5 years in hormone-sensitive, HER2-negative early-stage breast cancer.
SERENA-4 trial (Astra Zeneca): Camizestrant (oral SERD) + palbociclib + anastrozole placebo vs. anastrozole + palbociclib + SERD placebo for hormone-sensitive, HER2-negative, metastatic breast cancer.
SASCIA trial (Gilead, GBG): Phase III. Post-neoadjuvant trial to evaluate Sacituzumab Govitecan in primary HER2-negative breast cancer with an increased risk of recurrence and incomplete pathological remission after neoadjuvant chemotherapy.
EXPERT (Breast Cancer Trials): Phase III clinical trial in patients with early-stage unifocal node-negative luminal A breast carcinoma (maximum microscopic size of invasive carcinoma ≤2 cm, hormone receptor-positive, HER2-negative, histology grade 1 or 2); Patients undergo a multigene test (PAM 50/Prosigna) to assess their risk of recurrence. After breast-conserving surgery, low-risk patients (≤60 ROR) are randomly selected to receive either radiotherapy and endocrine therapy or endocrine therapy alone.
ASCENT-04: Phase III clinical trial, for patients with PD-L1-positive triple-negative breast cancer that is locally advanced and inoperable or metastatic. Patients are randomly assigned to one of two treatments (randomisation): Sacituzumab Govitecan (antibody-drug conjugate) in combination with immunotherapy (Pembrolizumab) or standard chemotherapy combined with immunotherapy (Pembrolizumab).
HER2CLIMB-05: Phase III double-blind clinical trial, for patients with Her2-positive metastatic breast cancer. The patients are randomly assigned to one of two treatments (randomisation): trial therapy with Tucatinib (anti-HER2 Tyrosine-Kinase inhibitor) or placebo. All patients also receive standard Her2-targeted maintenance therapy with Trastuzumab and Pertuzumab.
POLAR: Phase III clinical trial, for patients with hormone receptor-positive, Her2-negative breast cancer with locoregional recurrence. Patients have been randomly assigned to one of two treatments (randomisation): Standard endocrine therapy combined with CDK4/6 inhibitor (Palbociclib) or standard endocrine therapy without CDK4/6 inhibitor (Palbociclib).
TAXIS: Phase III clinical trial, for patients with breast cancer and affected lymph nodes in the armpit (axilla). Patients are randomly assigned to one of two treatments (randomisation): control group (Arm A): Targeted lymph node removal with extended axillary lymph node removal (in the sense of classic axillary lymph node surgery) plus radiotherapy of the lymph nodes, excluding the surgically treated axillary area. Trial group (Arm B): Targeted axillary lymph node removal plus radiotherapy of the entire axilla.
Completed trials (follow-up completed)
SOLE trial (IBCSG 35/07): Evaluation of the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, lymph node-positive, early-stage breast cancer.
SENTINEL trial (IBCSG 23/09): A randomised trial comparing axillary dissection with no axillary dissection in patients with clinically node-negative breast cancer and micrometastases in the sentinel node.
TACHOSIL trial (SAKK 23/13): Effects of a surgical sealant patch on lymph drainage following axillary lymph node removal in breast cancer. A multicentre randomised phase III trial.
SKINI trial (Breast Centre): Prospective evaluation of the radicality of breast tissue removal in skin- and nipple-sparing mastectomies (SSM or NSM).
OncotypeDX trial (SAKK 26/10): Influence of the Recurrence Score® on treatment recommendations for patients with ER-positive breast cancer.
PRIME trial: Prospective trial to measure the impact of MammaPrint on adjuvant treatment in hormone receptor-positive, HER2-negative breast cancer patients.
ALTTO trial (IBCSG 36–07): Adjuvant chemotherapy + Herceptin and/or lapatinib.
NEOSPHERE and TRYPHAENA trials (Roche): NEOSPHERE and TRYPHAENA trial (Roche): Neoadjuvant chemotherapy/Herceptin +/- Pertuzumab.
PREFHER trial (Roche): Adjuvant Herceptin intravenously vs. subcutaneously.
Elderly trial (SAKK 25/14): Eribulin as first-line therapy in older patients (≥ 70 years) with advanced breast cancer: A multicentre phase II trial.
Consilium trial: Efficiency of the Consilium smartphone app for detecting symptoms and treatment side effects in cancer patients depending on the form of medication application, age and outpatient characteristics: Observational trial (OnkoZentrum Zurich).
KAITLIN trial (Roche): Adjuvant chemotherapy/T-DM1/Herceptin/Pertuzumab.
eMonarcHER trial (Lilly): Endocrine therapy + abemaciclib vs. endocrine therapy + placebo in node-positive, hormone-sensitive, HER2-positive early-stage breast cancer (no patients included, early recruitment stop).
TOUCH trial (IBCSG 55–17): Neoadjuvant palbociclib plus letrozole and dual HER2 blockade versus Paclitaxel plus dual HER2 blockade in postmenopausal patients with hormone-sensitive, HER2-positive breast carcinoma.
EPIK-B3 trial (Novartis): Alpelisib (BYL719) in combination with nab-paclitaxel in advanced triple-negative breast cancer with PIK3CA mutation and/or PTEN loss without PIK3CA mutation (no patients included).
WISE trial (IBCSG 95–17): 24-week activity programme for patients with early-stage breast cancer receiving aromatase inhibitor therapy.
ELEANOR trial (Pierre Fabre, CRO: iOMEDICO): Phase IV observational study. Neratinib for 1 year in hormone-sensitive, HER2-positive breast cancer within 1 year of completing anti-HER2 therapy.
Metformin trial (IBCSG 40–11): Metformin vs. Placebo for hormone-sensitive, HER2-negative breast cancer over 5 years in combination with endocrine therapy.
SOFT trial (IBCSG 24/05) for premenopausal patients: Tamoxifen vs. tamoxifen with GnRH vs. Aromasin with GnRH.
APHINITY trial: Adjuvant chemotherapy in combination with Herceptin and Pertuzumab.
TROG trial: Radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast.
KATHERINE trial: T-DM1 vs. Herceptin in cases of incomplete pathological remission following neoadjuvant chemotherapy.
REDUSE trial (SAKK 96/12): Denosumab trial, denosumab once monthly vs. every three months in metastatic breast carcinoma with ≥3 bone metastases.
IMPASSION 030 trial (Roche): Atezolizumab (anti-PD-L1 AK) in combination with adjuvant chemotherapy (taxane/anthracycline-based) vs. adjuvant chemotherapy alone in operable triple-negative breast cancer.
LASER (Novian Health): Confirmatory trial in patients with breast tumours measuring 15 mm or smaller; Trial procedure: Ablation of the tumour with Novilase® laser, followed by surgery on the primary tumour and further treatment according to standard procedure.
MALLORCA (Affidea brustCare): Prospective randomised trial in patients with node-positive breast cancer studying the importance of preoperative marker technology for efficient and safe targeted lymph node removal; random allocation for lymph node marking with: HydroMARK© Clip versus Pintuition seed.
TARGIT-A trial (UCL London): Comparison of intraoperative radiation therapy (IORT) alone with conventional radiotherapy.
ASCENT-03: Phase III clinical trial, for patients with triple-negative breast cancer that is locally advanced and inoperable or metastatic, and who: is PD-L1 negative or is PD-L1-positive but has previously been treated with an adjuvant anti-PD-L1 inhibitor. Patients are randomly assigned to one of two treatments (randomisation): Sacituzumab Govitecan (antibody-drug conjugate) or standard chemotherapy.
PROMs: Cohort study with survey of patients undergoing oncoplastic breast-conserving surgery. Assessment of treatment satisfaction and health-related quality of life using the BREAST-Q™ questionnaire. All participants receive the BREAST-Q™ questionnaire pre- and post-operatively at intervals of 4 weeks, 6 months and 1 year.